Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Leslie Padrnos & Ruben Mesa. (2020) Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials. Expert Opinion on Investigational Drugs 29:8, pages 809-817.
Read now
Read now
Helen T. Chifotides, Prithviraj Bose & Srdan Verstovsek. (2020) Givinostat: an emerging treatment for polycythemia vera. Expert Opinion on Investigational Drugs 29:6, pages 525-536.
Read now
Read now
Andrew L Sochacki, Melissa A Fischer & Michael R Savona. (2016) Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. OncoTargets and Therapy 9, pages 2273-2286.
Read now
Read now
Nidhi Tandon, Vijay Ramakrishnan & Shaji K Kumar. (2016) Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clinical Pharmacology: Advances and Applications 8, pages 35-44.
Read now
Read now
Prithviraj Bose & Srdan Verstovsek. (2016) Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opinion on Investigational Drugs 25:12, pages 1393-1403.
Read now
Read now
A Tedjaseputra, S Galli, M Ibrahim, CN Harrison & DP McLornan. (2016) Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects. Expert Opinion on Orphan Drugs 4:4, pages 417-427.
Read now
Read now
Brady L. Stein, Francisco Cervantes, Francis Giles, Claire N. Harrison & Srdan Verstovsek. (2015) Novel therapies for myelofibrosis. Leukemia & Lymphoma 56:10, pages 2768-2778.
Read now
Read now
Holly L Geyer & Ruben A Mesa. (2015) Emerging drugs for the treatment of myelofibrosis. Expert Opinion on Emerging Drugs 20:4, pages 663-678.
Read now
Read now
Sridurga Mithraprabhu, Anna Kalff, Annie Chow, Tiffany Khong & Andrew Spencer. (2014) Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics 9:11, pages 1511-1520.
Read now
Read now
Lisa Pieri, Paola Guglielmelli, Guido Finazzi & Alessandro M Vannucchi. (2014)
Givinostat for the treatment of polycythemia vera. Expert Opinion on Orphan Drugs 2:8, pages 841-850.
Read now
Read now
Claire N Harrison & Michael Bennett. (2014) Orphan drugs for myelofibrosis. Expert Opinion on Orphan Drugs 2:4, pages 391-405.
Read now
Read now
Karoline Gäbler, Iris Behrmann & Claude Haan. (2013) JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAK-STAT 2:3.
Read now
Read now
Raoul Tibes, James M Bogenberger, Holly L Geyer & Ruben A Mesa. (2012) JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opinion on Investigational Drugs 21:12, pages 1755-1774.
Read now
Read now
Mamatha M Reddy, Anagha Deshpande & Martin Sattler. (2012) Targeting JAK2 in the therapy of myeloproliferative neoplasms. Expert Opinion on Therapeutic Targets 16:3, pages 313-324.
Read now
Read now
Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse & Hans Carl Hasselbalch. (2012) Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia & Lymphoma 53:1, pages 123-129.
Read now
Read now
Ayalew Tefferi. (2008) Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Leukemia & Lymphoma 49:12, pages 2231-2232.
Read now
Read now
Articles from other publishers (33)
Amit Kundu, Sreevarsha Gali, Swati Sharma, Jae Hyeon Park, So Young Kyung, Sam Kacew, In Su Kim, Kwang Youl Lee & Hyung Sik Kim. (2022) Tenovin-1 Ameliorates Renal Fibrosis in High-Fat-Diet-Induced Diabetic Nephropathy via Antioxidant and Anti-Inflammatory Pathways. Antioxidants 11:9, pages 1812.
Crossref
Crossref
Kristen Pettit, Alexandra Rezazadeh, Ehab L. Atallah & Jerald Radich. (2022) Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. American Society of Clinical Oncology Educational Book:42, pages 595-613.
Crossref
Crossref
Lisa Chu & Kristen Pettit. (2022) Advances in Janus-Associated Kinase Inhibitor-Based Therapies for Philadelphia Chromosome–Negative Myeloproliferative Neoplasms. Advances in Oncology 2:1, pages 179-194.
Crossref
Crossref
Maria Teresa Bochicchio, Valeria Di Battista, Pietro Poggio, Giovanna Carrà, Alessandro Morotti, Mara Brancaccio & Alessandro Lucchesi. (2022) Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms. Cancers 14:4, pages 972.
Crossref
Crossref
Cinzia Caprio, Antonio Sacco, Viviana Giustini & Aldo M. Roccaro. (2020) Epigenetic Aberrations in Multiple Myeloma. Cancers 12:10, pages 2996.
Crossref
Crossref
Xing Hao, Wen Xing, Jiajia Yuan, Yingshao Wang, Jiaojiao Bai, Jie Bai & Yuan Zhou. (2019) Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. Investigational New Drugs 38:3, pages 610-620.
Crossref
Crossref
Amit Kundu, Sachan Richa, Prasanta Dey, Kyeong Seok Kim, Ji Yeon Son, Hae Ri Kim, Seok-Yong Lee, Byung-Hoon Lee, Kwang Youl Lee, Sam Kacew, Byung Mu Lee & Hyung Sik Kim. (2020) Protective effect of EX-527 against high-fat diet-induced diabetic nephropathy in Zucker rats. Toxicology and Applied Pharmacology 390, pages 114899.
Crossref
Crossref
J. Mascarenhas, B.K. Marcellino, M. Lu, M. Kremyanskaya, F. Fabris, L. Sandy, M. Mehrotra, J. Houldsworth, V. Najfeld, S. El Jamal, B. Petersen, E. Moshier & R. Hoffman. (2020) A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). Leukemia Research 88, pages 106272.
Crossref
Crossref
Johanna Ungerstedt. (2018) Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors. International Journal of Molecular Sciences 19:10, pages 3091.
Crossref
Crossref
Amir Hosseini & Saverio Minucci. 2018. Epigenetics in Human Disease. Epigenetics in Human Disease
141
217
.
Teresa L. Ramos, Luis Ignacio Sánchez-Abarca, Alba Redondo, Ángel Hernández-Hernández, Antonio M. Almeida, Noemí Puig, Concepción Rodríguez, Rebeca Ortega, Silvia Preciado, Ana Rico, Sandra Muntión, José Ramón González Porras, Consuelo Del Cañizo & Fermín Sánchez-Guijo. (2017) HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?. Oncotarget 8:17, pages 28187-28202.
Crossref
Crossref
Lindsey Shantzer, Kristin Berger & Jeffrey J. Pu. (2016) Primary myelofibrosis and its targeted therapy. Annals of Hematology 96:4, pages 531-535.
Crossref
Crossref
Rita Assi, Srdan Verstovsek & Naval Daver. (2017) ‘JAK–ing’ up the treatment of primary myelofibrosis. Current Opinion in Hematology 24:2, pages 115-124.
Crossref
Crossref
Ting Zhao, Yongqing Li, Baoling Liu, Baihong Pan, Xin Cheng, Patrick Georgoff & Hasan B. Alam. (2016) Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model. Journal of Trauma and Acute Care Surgery 80:1, pages 34-41.
Crossref
Crossref
Jason B. Kaplan, Brady L. Stein, Brandon McMahon, Francis J. Giles & Leonidas C. Platanias. (2016) Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms. EBioMedicine 3, pages 17-25.
Crossref
Crossref
Florence Pasquier, Xenia Cabagnols, Lise Secardin, Isabelle Plo & William Vainchenker. (2014) Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy. Clinical Lymphoma Myeloma and Leukemia 14, pages S23-S35.
Crossref
Crossref
Murugavel Ponnusamy, Xiaoxu Zhou, Yanli Yan, Jinhua Tang, Evelyn Tolbert, Ting C. Zhao, Rujun Gong & Shougang Zhuang. (2014) Blocking Sirtuin 1 and 2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy. Journal of Pharmacology and Experimental Therapeutics 350:2, pages 243-256.
Crossref
Crossref
Jonathan L. Kaufman, Claire Fabre, Sagar Lonial & Paul G. Richardson. (2013) Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 370-376.
Crossref
Crossref
Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Roman Hajek, Ivan Spicka, Meletios A. Dimopoulos, Philippe Moreau, David S. Siegel, Sundar Jagannath & Kenneth C. Anderson. (2013) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leukemia Research 37:7, pages 829-837.
Crossref
Crossref
Fabio P.S. Santos & Srdan Verstovsek. (2013) What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?. Current Opinion in Hematology 20:2, pages 123-129.
Crossref
Crossref
Shen-meng Gao, Chi-qi Chen, Lu-yao Wang, Li-li Hong, Jian-bo Wu, Pei-hong Dong & Fu-jun Yu. (2013) Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Experimental Hematology 41:3, pages 261-270.e4.
Crossref
Crossref
Nigel J. Pyne, Gerald Dubois & Susan Pyne. (2013) Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1831:1, pages 228-238.
Crossref
Crossref
Warren Fiskus, Siddhartha Ganguly, Suman Kambhampati & Kapil N. Bhalla. (2012) Role of Additional Novel Therapies in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America 26:5, pages 959-980.
Crossref
Crossref
Hajime AkadaSaeko AkadaAjeet Gajra, Alicia Bair, Stephen Graziano, Robert E. Hutchison & Golam Mohi. (2012) Efficacy of vorinostat in a murine model of polycythemia vera. Blood 119:16, pages 3779-3789.
Crossref
Crossref
Kai B. Kaufmann, Albert Gründer, Tobias Hadlich, Julius Wehrle, Monika Gothwal, Ruzhica Bogeska, Thalia S. Seeger, Sarah Kayser, Kien-Binh Pham, Jonas S. Jutzi, Lucas Ganzenmüller, Doris Steinemann, Brigitte Schlegelberger, Julia M. Wagner, Manfred Jung, Britta Will, Ulrich Steidl, Konrad Aumann, Martin Werner, Thomas Günther, Roland Schüle, Alessandro Rambaldi & Heike L. Pahl. (2012) A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. Journal of Experimental Medicine 209:1, pages 35-50.
Crossref
Crossref
Ciro Mercurio, Simon Plyte & Saverio Minucci. 2012. Epigenetics in Human Disease. Epigenetics in Human Disease
53
87
.
Fabio P. S. Santos & Srdan Verstovsek. 2012. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
215
232
.
J.C. Wang, M.I. Kafeel, B. Avezbakiyev, C. Chen, Y. Sun, C. Rathnasabapathy, M. Kalavar, Z. He, J. Burton & S. Lichter. (2011) Histone Deacetylase in Chronic Lymphocytic Leukemia. Oncology 81:5-6, pages 325-329.
Crossref
Crossref
Sridurga Mithraprabhu, George Grigoriadis, Tiffany Khong & Andrew Spencer. (2010) Deactylase inhibition in myeloproliferative neoplasms. Investigational New Drugs 28:S1, pages 50-57.
Crossref
Crossref
Maoyin Pang & Shougang Zhuang. (2010) Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders. Journal of Pharmacology and Experimental Therapeutics 335:2, pages 266-272.
Crossref
Crossref
Ciro Mercurio, Saverio Minucci & Pier Giuseppe Pelicci. (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological Research 62:1, pages 18-34.
Crossref
Crossref
Jinsheng Guo, Feng Hong, Johnny Loke, Steven Yea, Chooi Ling Lim, Ursula Lee, Derek A. Mann, Martin J. Walsh, John J. Sninsky & Scott L. Friedman. (2010) A DDX5 S480A Polymorphism Is Associated with Increased Transcription of Fibrogenic Genes in Hepatic Stellate Cells. Journal of Biological Chemistry 285:8, pages 5428-5437.
Crossref
Crossref
Alessandro M. Vannucchi, Paola Guglielmelli, Alessandro Rambaldi, Costanza Bogani & Tiziano Barbui. (2009) Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. Journal of Cellular and Molecular Medicine 13:8a, pages 1437-1450.
Crossref
Crossref